Pathios Therapeutics Limited, an Oxford, England, UK-based biotech company focused on the development of therapies for autoimmune diseases and cancer, raised US$8.8M in Series A financing.
Backers included Canaan and Australia’s Medical Research Commercialisation Fund managed by Brandon Capital.
The company intends to use the funds to advance its development programs.
Launched in 2017 by Tom McCarthy, Executive Chairman, Pathios is a drug discovery and development company focused on the development of modulators of GPR65. The company targets its signalling in cells of the immune system. Many pathological environments are characterized by abnormally acidic pH which signals to local immune cells leading to profound and unfavourable changes in their characteristics. A key mediator of these effects is GPR65 which is highly expressed on cells of both the adaptive and innate immune systems.
Pathios also announced the appointment of Stuart Hughes as Chief Executive Officer and Director. Formerly Senior Director and Head of Pharmacology at Vertex Pharmaceuticals (Europe) Limited, Hughes is seasoned in drug discovery and development, with experience leading translational drug development programs across a range of therapeutic areas.